Education
About Us
Working with TipRanks
Follow Us
NanoViricides (NNVC)
:NNVC
Top Page
NanoViricides
(NYSE MKT:NNVC)
Select Model
Select Model
Rating:42Neutral
Price Target:―
NanoViricides' overall score is mainly impacted by its weak financial performance due to lack of revenue and ongoing losses. While technical analysis indicates some short-term positive momentum, the company's valuation remains a concern given its negative earnings. The absence of earnings call data and corporate events limits potential positive catalysts.
NanoViricides (NNVC) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$22.82M
Dividend YieldN/A
Average Volume (3M)128.68K
Price to Earnings (P/E)―
Beta (1Y)0.44
Revenue GrowthN/A
EPS Growth13.83%
CountryUS
Employees7
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.72
Shares Outstanding16,072,000
10 Day Avg. Volume132,763
30 Day Avg. Volume128,679
Financial Highlights & Ratios
PEG Ratio0.49
Price to Book (P/B)1.92
Price to Sales (P/S)0.00
P/FCF Ratio-3.39
Enterprise Value/Market Cap0.73
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-21.61
Enterprise Value/Ebitda-1.82
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
NanoViricides Business Overview & Revenue Model
Company DescriptionNanoViricides, Inc., a nano-biopharmaceutical research and development company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company develops Human Coronavirus Program for COVID-19 seasonal coronavirus affliction; HerpeCide Dermal Topical and Eye Drops for the treatment of shingles, PHN, chickenpox, herpes, recurrent herpes labialis, genital herpes, and ocular herpes keratitis; and HerpeCide IntraOcular Injection for viral acute retinal necrosis The company also develops FluCide Broad-Spectrum Anti-Influenza nanoviricide, which is injectable for hospitalized patients and oral for outpatients; Nanoviricide eye drops for viral diseases of the external eye; DengueCide for treatment of various types of Dengue viruses; and HIVCide, an escape-resistant anti-HIV nanoviricide. In addition, it develops other nanoviricides drug projects for treatment of different viruses and indications; and HerpeCide program expansion drug projects for different herpes viruses for different indications. NanoViricides, Inc. was founded in 2005 and is based in Shelton, Connecticut.
How the Company Makes MoneyNanoViricides makes money primarily through the development and commercialization of its proprietary antiviral drug candidates. As the company is primarily in the research and development phase, its current revenue streams are limited to potential grants, research collaborations, and licensing agreements with larger pharmaceutical companies. These partnerships can provide funding and resources in exchange for rights to develop or market NanoViricides' technologies. Additionally, the company may earn revenue in the future through product sales once its drugs receive regulatory approval and are launched in the market. Until then, its financial health is heavily reliant on investment funding and strategic partnerships to support its ongoing research activities.
NanoViricides Financial Statement Overview
Summary
NanoViricides is facing significant financial challenges characterized by lack of revenue, consistent operational losses, and cash burn. While the capital structure shows no debt, the reliance on equity and financing for operations underscores the urgency for revenue generation to ensure long-term viability.Income Statement
NanoViricides has not generated any revenue in the TTM (Trailing-Twelve-Months) or previous years, leading to consistent negative gross and net profit margins. The company operates at a loss with EBIT and EBITDA margins also being negative, indicating ongoing financial challenges.20
Very Negative
Balance Sheet
The company maintains a favorable debt position with zero total debt in the latest TTM, resulting in a strong equity ratio. However, the declining stockholders' equity and total assets over time suggest potential concerns regarding asset management and equity preservation.50
Neutral
Cash Flow
NanoViricides has negative operating and free cash flows, indicating cash burn without revenue generation. The company relies on financing activities to support operations, which may not be sustainable long-term without revenue growth.35
Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -773.28K | -759.01K | -747.53K | -723.33K | -704.54K | -699.72K |
| EBITDA | -9.18M | -7.49M | -7.84M | -7.38M | -8.03M | -7.30M |
| Net Income | -9.73M | -8.29M | -8.59M | -8.10M | -8.91M | -13.40M |
Balance Sheet | ||||||
| Total Assets | 10.03M | 12.82M | 16.90M | 23.49M | 30.26M | 23.91M |
| Cash, Cash Equivalents and Short-Term Investments | 2.54M | 4.80M | 8.15M | 14.07M | 20.52M | 13.71M |
| Total Debt | 0.00 | 0.00 | 0.00 | 94.79K | 95.31K | 1.14M |
| Total Liabilities | 1.20M | 1.36M | 2.03M | 412.84K | 351.15K | 2.16M |
| Stockholders Equity | 8.83M | 11.46M | 14.87M | 23.08M | 29.91M | 21.76M |
Cash Flow | ||||||
| Free Cash Flow | -8.40M | -6.47M | -5.82M | -6.22M | -8.45M | -6.67M |
| Operating Cash Flow | -8.26M | -6.32M | -5.67M | -5.89M | -8.21M | -6.67M |
| Investing Cash Flow | -144.93K | -156.56K | -151.71K | -324.35K | -238.76K | -8.64K |
| Financing Cash Flow | 7.69M | 3.12M | -94.79K | -234.72K | 15.26M | 17.83M |
NanoViricides Technical Analysis
Negative
1.42
Price Trends
1.51
Negative
1.48
Negative
1.39
Positive
Market Momentum
-0.01
Negative
45.92
Neutral
29.28
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NNVC, the sentiment is Negative. The current price of 1.42 is below the 20-day moving average (MA) of 1.43, below the 50-day MA of 1.51, and above the 200-day MA of 1.39, indicating a neutral trend. The MACD of -0.01 indicates Negative momentum. The RSI at 45.92 is Neutral, neither overbought nor oversold. The STOCH value of 29.28 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NNVC.
NanoViricides Risk Analysis
NanoViricides disclosed 50 risk factors in its most recent earnings report. NanoViricides reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
NanoViricides Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | $123.02M | -3.22 | -38.74% | ― | 1071.91% | -27.61% | |
53 Neutral | $16.18M | -2.04 | ― | ― | -96.76% | 26.87% | |
42 Neutral | $22.82M | ― | -99.84% | ― | ― | 13.83% | |
39 Underperform | $43.03M | -1.93 | ― | ― | ― | 15.19% | |
36 Underperform | $24.57M | -1.82 | ― | ― | ― | 52.51% | |
36 Underperform | $33.12M | -7.86 | ― | ― | ― | 95.87% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
NNVC
NanoViricides
1.42
-0.08
-5.33%
ENLV
Enlivex
1.03
-0.65
-38.69%
TENX
Tenax Therapeutics
7.26
3.80
109.83%
PULM
Pulmatrix
4.43
2.29
107.01%
OVID
Ovid Therapeutics
1.73
0.55
46.61%
CALC
CalciMedica
3.08
-1.35
-30.47%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.